Shanghai, China - On July 29, 2021, Alwide® Plus, the next-generation valve balloon dilation catheter developed by MicroPort® CardioFlow Medtech Corporation, CardioFlow Medtech), was approved for marketing by China’s National Medical Products Administration (NMPA). The marketing approval further enriches CardioFlow Medtech’s product portfolio of total valve solutions, supporting TAVR surgeons to treat a wider range of patient types.
Since its launch in 2019, the Alwide® balloon catheter has been used in over 2,000 procedures across more than 220 cardiac centers in China. It is widely recognized by surgeons for its performance, and provides a new alternative to the existing range of balloon dilatation catheter products for TAVR surgery. Alwide® Plus is an upgraded version of Alwide®, featuring a low compliance profile. Designed to provide precise inflation sizing, its high burst pressure responds better to severe calcification commonly found among patients in China. At the same time, Alwide® Plus minimizes the pacing time, thanks to its faster inflation and deflation speed. Alwide® Plus has significantly improved its burst pressure and sheath design at the distal end of the catheter, resulting in a better user experience and increased safety of intraoperative balloon dilation[1].
About MicroPort® CardioFlow Medtech Corporation
Founded in 2015, CardioFlow Medtech (stock code: 02160.HK) specializes in total medical solutions for the treatment of the most common aortic and mitral valve diseases, including aortic stenosis and mitral regurgitation. Its independently developed VitaFlow® Transcatheter Aortic Valve and Delivery System received NMPA approval in July 2019. The new generation product, VitaFlow Liberty Transcatheter Aortic Valve and Delivery System, has processed registration and is under clinical trials in Europe. In clinical practices, VitaFlow® has been paired with CardioFlow Medtech’s proprietary Alwide® valve balloon dilation catheter and Alpass® catheter sheath, which have enabled CardioFlow Medtech to become the only medical device company in China that can provide a comprehensive offering of accessories for TAVI procedures.
[1] Clinical Results from CardioFlow Medtech